Randomized trials have revealed that anti-PD-1/PD-L1 plus platinum-based chemotherapy (PBC) provides additional benefits in both overall survival (OS) and progression-free survival (PFS) for patients with advanced NSCLC, compared with chemotherapy alone in first-line treatment (5–10). This evidence concerns the gene PDCD1 and non-small cell lung carcinoma.